Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.

Marc P E AndréPatrice CardeSimonetta VivianiMonica BelleiCatherine FortpiedMartin HutchingsAlessandro M GianniPauline BriceOlivier CasasnovasPaolo G GobbiPier Luigi Luigi ZinzaniJehan DupuisEmilio IannittoAlessandro RambaldiJosette BrièreLaurianne Clément-FilliatreMarian HeczkoPinuccia ValagussaJonathan DouxfilsJulien DepausMassimo FedericoNicolas Mounier

Published in: Cancer medicine (2020)

This analysis showed a slight improvement in OS for BEACOPP and confirmed a PFS benefit. Frontline use of BEACOPP instead of ABVD increased secondary leukemia incidence but halved the requirement for ASCT.

Keyphrases

hodgkin lymphoma
acute myeloid leukemia
risk factors
bone marrow
clinical trial
randomized controlled trial
phase iii